Absence of Scavenger Receptor A Promotes Dendritic Cell-mediated Cross-presentation of Cell-associated Antigen and Antitumor Immune Response
Overview
Cell Biology
Affiliations
Given the primary expression of scavenger receptor A (SRA) or CD204 on antigen-presenting cells, we investigate the immunoregulatory activities of SRA/CD204 in the context of cross-presentation of cell-associated antigen and the immunogenicity of dying tumor cells. Immunization with dying prostate cancer cells results in profoundly increased control of subsequently inoculated tumors in SRA/CD204 knockout mice. Using OVA-expressing RM1 prostate tumor line (RM1-OVA), we show for the first time that SRA absence greatly enhances dendritic cells (DCs)-mediated cross-presentation of OVA antigen derived from dying RM1 cells. While the phagocytic ability of DCs is not significantly impacted by the lack of SRA/CD204, DCs deficient in SRA/CD204 display increased expression of inflammatory cytokines and chemokines, as well as co-stimulatory molecules upon interaction with dying RM1 cells, implicating a suppressive regulation of the functional activation of DCs by SRA/CD204. Further, SRA/CD204-deficient DCs pulsed with dying RM1-OVA cells are more effective than wild-type counterparts in priming antigen-specific T-cell responses, resulting in improved control of RM1 tumor growth in both prophylactic and therapeutic settings. Our findings suggest that the increased immunogenicity of dying tumor cells in SRA/CD204 knockout mice is attributed to the altered functions of DCs in the absence of SRA/CD204, which underscores the important role of SRA/CD204 in host immune homeostasis. Selective downregulation or blockade of this immunoregulatory molecule may lead to enhanced potency of DC-based vaccines capable of breaking immune tolerance against cancer.
Deficiency of SR-B1 reduced the tumor load of colitis-induced or APC -induced colorectal cancer.
Chen Q, Wang L, Song H, Xing W, Shi J, Li Y Cancer Med. 2023; 12(19):19744-19757.
PMID: 37766594 PMC: 10587988. DOI: 10.1002/cam4.6534.
Liu Z, Liu W, Wang W, Ma Y, Wang Y, Drum D Proc Natl Acad Sci U S A. 2023; 120(39):e2302878120.
PMID: 37722058 PMC: 10523454. DOI: 10.1073/pnas.2302878120.
SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine.
Qian J, Yu X, Liu Z, Cai J, Manjili M, Yang H Front Immunol. 2023; 14:1118781.
PMID: 36793731 PMC: 9923017. DOI: 10.3389/fimmu.2023.1118781.
Electrical Stimulation for Immune Modulation in Cancer Treatments.
Das R, Langou S, Le T, Prasad P, Lin F, Nguyen T Front Bioeng Biotechnol. 2022; 9:795300.
PMID: 35087799 PMC: 8788921. DOI: 10.3389/fbioe.2021.795300.
Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
Liu Z, Guo C, Das S, Yu X, Pradhan A, Li X Cancer Res. 2021; 81(9):2429-2441.
PMID: 33727225 PMC: 8362838. DOI: 10.1158/0008-5472.CAN-20-2604.